Clinical trial
Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease
NCT01058018 is registered in ClinicalTrials.gov with Resverlogix Corp as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease
- Lead sponsor
- Resverlogix Corp
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2009
- Completion date
- September 30, 2010
- Enrollment
- 299 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.